Obesity Type 2 Diabetes MellitusDINE-GLP1NCT07313384
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
An observational study of Obesity Type 2 Diabetes Mellitus and Obesity (Disorder), run by University of South Carolina at 2 sites in United States.
Trial summary
The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity Type 2 Diabetes Mellitus, Obesity (Disorder)
- What is being tested?
- GLP-1 Therapy
- How many people
- 50 participants
- Where
- 2 sitesUnited States
- Study dates
- 11 Feb 2026to 1 Dec 2026
- How long will I take part?
- 12 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The recruitment will be conducted at the Prisma Health Weight Management Institute in Greenville, South Carolina, with support from the on-site research team. A total of 50 patients will be enrolled. Eligible individuals will be adults aged 18 years or older who have recently been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication.
Who may be able to join
- Adults aged 18 and older
- Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication
- Has regular access to a smartphone and internet to complete short surveys and food recalls online
- Willing to sign informed consent.
Who cannot join
- Already began the GLP-1 medication
- Have medical concerns making participation unsafe
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University South Carolina
Columbia, South Carolina, 20208
Prisma Health Weight Management Institute
Greenville, South Carolina, 29607
About this study
The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.
- Being tested
- GLP-1 Therapy
- Keywords
- GLP-1 Therapy, Nutrition Support, Obesity, Weight loss therapy
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 TherapyDrug
Exposure to GLP-1 Therapy for obesity or T2DM management.
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 Therapy | Individuals prescribed with GLP-1 Therapy for obesity or T2DM management. Receives: Drug: GLP-1 Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Healthy Eating Index
The Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.
Measured: Baseline and 12-weeks
Secondary outcomes (1)
Change in Body Weight
Change from Baseline in Body Weight at 12-weeks
Measured: Baseline and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study start11 Feb 2026
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by University of South CarolinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
- Target duration
- 12 Weeks
Sponsor and investigators
- Lead sponsor
- University of South Carolina
- Sponsor type
- University, hospital or other
- Collaborators
- Prisma Health-Upstate
- Responsible party
- Principal investigator, Shiba Simon Bailey, University of South Carolina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07313384
- Sponsor's protocol ID
- 2371702-1
- Acronym
- DINE-GLP1
- Status last verified
- Feb 2026
- First submitted
- 1 Dec 2025
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
- ClinicalTrials.gov ID
- NCT07313384
- Acronym / sponsor ID
- DINE-GLP1 / 2371702-1
- Keywords
- GLP-1 Therapy, Nutrition Support, Obesity, Weight loss therapy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of South CarolinaUniversity, hospital or other
- Collaborators
- Prisma Health-Upstate
- Study start
- 11 Feb 2026 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GLP-1 Therapy | – | Drug: GLP-1 TherapyIndividuals prescribed with GLP-1 Therapy for obesity or T2DM management. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The recruitment will be conducted at the Prisma Health Weight Management Institute in Greenville, South Carolina, with support from the on-site research team. A total of 50 patients will be enrolled. Eligible individuals will be adults aged 18 years or older who have recently been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication.
Key inclusion criteria (4 listed)
- Adults aged 18 and older
- Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication
- Has regular access to a smartphone and internet to complete short surveys and food recalls online
- Willing to sign informed consent.
Key exclusion criteria (2 listed)
- Already began the GLP-1 medication
- Have medical concerns making participation unsafe
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1 TherapyExposure to GLP-1 Therapy for obesity or T2DM management. | Drug | GLP-1 Therapy |
Primary outcome
Change in Healthy Eating Index
Time frame: Baseline and 12-weeks
The Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.
1 secondary outcome
Change in Body Weight
Time frame: Baseline and 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Obesity Type 2 Diabetes Mellitus
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Active, not recruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes Mellitus, Overweight
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Not yet recruitingObservational study
Obesity-Related Indices and Albuminuria in Type 2 Diabetes
Obesity and Diabetes Mellitus, Type 2, Albuminuria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity Type 2 Diabetes Mellitus and Obesity (Disorder), run by University of South Carolina at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Healthy Eating Index (time frame: Baseline and 12-weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.